Montgomery Co. LLC Initiates Coverage of Trubion Pharmaceuticals Inc. TRBN



Montgomery & Co., LLC, a leading investment bank for growth companies in the information technology, communications, healthcare, and media sectors, announced today that Principal and Analyst Shiv S. Kapoor (http://www.monty.com/biography.phpsection=Team'subsection=Research&id=261) has initiated coverage of Trubion Pharmaceuticals, Inc. (TRBN - $19.11). Founded in 1999, Trubion is a Seattle-based biopharmaceutical company focusing on the discovery, development, and commercialization of a novel class of protein therapeutics for the treatment of autoimmune diseases and cancer. Trubion's lead candidate, TRU-015, is currently in a Phase IIb trial for the treatment of rheumatoid arthritis (RA).

About Montgomery & Co., LLC

Founded in 1986, Montgomery & Co. is a full-service investment bank focused on the media, communications, technology, and healthcare industries. Montgomery & Co. provides research, sales & trading coverage, strategic advisory and M&A services, and public and private financings to growth companies in the information technology, communications, healthcare, and media & entertainment businesses.

As part of the Equity Capital Markets Group, the research analysts' mandate is to find undercovered growth companies in technology and healthcare in order to provide value-added services to the firm's clients.

Montgomery & Co.'s primary offices are in Santa Monica, San Francisco, and San Diego. Montgomery & Co. is a member of the National Association of Security Dealers, Inc. (NASD), and its professional associates are registered with the NASD-SIPC. For more information, please visit www.monty.com.

For additional information, please call     

Catherine Calleja

Montgomery & Co., LLC

310.260.6934





Montgomery Co. LLC Initiates Coverage of Trubion Pharmaceuticals Inc. TRBN